Longitude Capital is a venture capital investment firm based in Menlo Park, California, with additional offices in Greenwich and Boston. Founded in 1997, the firm focuses on venture growth investments in biotechnology and medical technology companies that aim to enhance clinical outcomes, improve quality of life, and reduce healthcare costs. Longitude Capital invests in both privately held and publicly traded life science companies, employing a range of investment strategies. The firm has raised over $1.2 billion across three funds since 2006, demonstrating expertise in sourcing, managing, and exiting investments across various market cycles. Their investment strategy emphasizes a balanced portfolio of clinical-stage and commercial-stage companies with clinically de-risked assets and favorable valuations. Longitude Capital identifies new opportunities through a robust network of industry relationships and thematic research into emerging therapeutic areas. The firm utilizes diverse investment structures, including traditional venture capital, asset spin-outs, recapitalizations, and royalties, among others.
MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating various neurological diseases. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation (VNS) to address conditions such as tinnitus, chronic pain, and rehabilitation for stroke survivors. Its notable products include the Serenity System, designed specifically for tinnitus treatment, and the Vivistim device, which is FDA approved for assisting ischemic stroke survivors with moderate to severe upper limb impairment. Through its innovative approaches, MicroTransponder aims to enhance recovery and improve the quality of life for individuals affected by these neurological conditions.
Molecular Templates
Post in 2017
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.